Reproductive Endocrinology Practice Questions

Q: A patient with spontaneous abortion presents with a history of amenorrhea and an FSH level of 6 IU/mL. What is the most likely diagnosis?

Uterine synechiae. **Explanation:** The clinical presentation of amenorrhea following a spontaneous abortion (which often involves a D&C procedure) combined with a **normal FSH level (6 IU/mL)** strongly points towards an anatomical cause rather than a hormonal one. **1. Why Uterine Synechiae is correct:** Uterine synechiae, or **Asherman Syndrome**, is the most common cause of secondary amenorrhea following intrauterine instrumentation (like curettage for abortion). The normal FSH level indicates that the Hypothalamic-Pituitary-Ovarian (HPO) axis is intact and functioning correctly. The amenorrhea is "outflow tract" related; the endometrium has been replaced by adhesions, making it unresponsive to hormonal stimulation. **2. Why other options are incorrect:** * **Ovarian Failure:** This would present with **Hypergonadotropic Hypogonadism**. You would expect a significantly elevated FSH (>25–40 IU/mL) due to the lack of negative feedback from estrogen. * **Pituitary Failure:** This would present with **Hypogonadotropic Hypogonadism**. You would expect very low or undetectable levels of FSH and LH. * **Pregnancy:** While pregnancy causes amenorrhea and a low/normal FSH, the question specifies the patient *had* a spontaneous abortion. If she were currently pregnant, the beta-hCG would be elevated, but "Uterine synechiae" is the classic "post-procedure" diagnosis tested in this context. **NEET-PG High-Yield Pearls:** * **Asherman Syndrome** is the most common cause of secondary amenorrhea where the Progesterone Challenge Test is **negative**. * **Gold Standard Investigation:** Hysteroscopy (both for diagnosis and adhesiolysis). * **Normal FSH Range:** 5–10 IU/mL. Always check FSH to differentiate between central (pituitary/hypothalamus), peripheral (ovarian), or anatomical (uterine) causes of amenorrhea.

Q: What is the most common cause of heterosexual development in a female at the expected age of puberty?

Polycystic ovarian syndrome. **Explanation:** The question asks for the most common cause of **heterosexual development** (virilization or signs of masculinization) in a female at the **expected age of puberty**. **1. Why Polycystic Ovarian Syndrome (PCOS) is correct:** PCOS is the most common endocrinopathy in women of reproductive age. While it typically presents post-menarche, it frequently manifests during the peripubertal period with signs of hyperandrogenism such as hirsutism, acne, and irregular cycles. Because of its high prevalence (5–10% of the female population), it remains the most common cause of heterosexual pubertal development compared to rarer genetic or enzymatic disorders. **2. Why the other options are incorrect:** * **Congenital Adrenal Hyperplasia (CAH):** While a major cause of virilization, the *classical* form presents at birth with ambiguous genitalia. The *non-classical* (late-onset) form can present at puberty, but its prevalence is significantly lower than PCOS. * **Pure Gonadal Dysgenesis (46,XX or 46,XY/Swyer):** This typically presents with **sexual infantilism** (failure of pubertal development) and primary amenorrhea due to streak gonads and lack of estrogen, not virilization. * **Complete Androgen Insensitivity Syndrome (CAIS):** These individuals are genotypically male (46,XY) but phenotypically female. They present with primary amenorrhea and a "hyper-feminized" appearance (large breasts, absent pubic hair) due to androgen resistance, not heterosexual development. **Clinical Pearls for NEET-PG:** * **Most common cause of ambiguous genitalia in a newborn:** CAH (21-hydroxylase deficiency). * **Most common cause of primary amenorrhea with absent uterus:** MRKH Syndrome (46,XX) or CAIS (46,XY). * **Key PCOS Diagnostic Criteria (Rotterdam):** 1. Hyperandrogenism, 2. Oligo/anovulation, 3. Polycystic ovaries on ultrasound (2 out of 3 required).

Q: Which of the following is NOT typically associated with Polycystic Ovary Syndrome?

Hypertension. **Explanation:** Polycystic Ovary Syndrome (PCOS) is primarily a metabolic and endocrine disorder characterized by hyperandrogenism, insulin resistance, and ovulatory dysfunction. While PCOS is a significant risk factor for developing metabolic syndrome, **Hypertension (Option A)** is not a diagnostic feature or a typical direct association of the syndrome itself. While long-term metabolic complications may eventually lead to cardiovascular issues, hypertension is not considered a hallmark of PCOS in the same way as the other options. **Why the other options are incorrect:** * **Diabetes Mellitus (Option B):** Insulin resistance is a core pathophysiological mechanism in PCOS. This leads to compensatory hyperinsulinemia, significantly increasing the risk of Impaired Glucose Tolerance and Type 2 Diabetes Mellitus. * **Obesity (Option C):** Approximately 50-80% of women with PCOS are obese. Adipose tissue exacerbates insulin resistance and contributes to the peripheral conversion of androgens to estrogens, worsening the hormonal imbalance. * **Hirsutism (Option D):** This is a clinical manifestation of hyperandrogenism (excessive terminal hair growth in a male-pattern distribution). It is one of the three criteria in the **Rotterdam Criteria** used to diagnose PCOS. **NEET-PG High-Yield Pearls:** * **Rotterdam Criteria (2 out of 3):** 1. Oligo/Anovulation, 2. Clinical/Biochemical Hyperandrogenism, 3. Polycystic ovaries on Ultrasound (≥12 follicles or volume >10cc). * **LH:FSH Ratio:** Classically elevated (3:1), though no longer a diagnostic requirement. * **Gold Standard Treatment for Infertility:** Letrozole (Aromatase inhibitor) is now preferred over Clomiphene Citrate. * **Hirsutism Scoring:** Modified Ferriman-Gallwey score (Score ≥8 is significant in Indians).

Q: GnRH analogues are useful in all of the following conditions except:

Hyperprolactinemia. **Explanation:** GnRH (Gonadotropin-Releasing Hormone) analogues work by initially stimulating and then paradoxically down-regulating the pituitary GnRH receptors. This leads to a state of **hypogonadotropic hypogonadism** (pseudomenopause), which is the therapeutic goal in estrogen-dependent conditions. **Why Hyperprolactinemia is the Correct Answer:** Hyperprolactinemia is primarily managed with **Dopamine agonists** (e.g., Cabergoline, Bromocriptine). Dopamine acts as the natural prolactin-inhibiting factor. GnRH analogues have no physiological role in suppressing prolactin secretion; in fact, hyperprolactinemia itself causes infertility by suppressing GnRH pulsatility. **Analysis of Other Options:** * **Endometriosis:** GnRH analogues are a gold-standard medical treatment. By inducing a hypoestrogenic state, they cause atrophy of ectopic endometrial tissue and provide symptomatic relief from pelvic pain. * **Precocious Puberty:** In Central Precocious Puberty, continuous GnRH analogues are used to desensitize the pituitary, stopping the premature secretion of LH/FSH and preventing early epiphyseal closure (preserving adult height). * **Menstrual Disturbances:** They are used to manage heavy menstrual bleeding in conditions like **Uterine Fibroids** (to shrink the tumor before surgery) and **Dysfunctional Uterine Bleeding (DUB)** refractory to other medical therapies. **NEET-PG High-Yield Pearls:** * **Flare Effect:** Initial administration causes a transient rise in gonadotropins. To prevent this in conditions like prostate cancer, anti-androgens are co-administered. * **Add-back Therapy:** To prevent bone mineral density loss and vasomotor symptoms during long-term GnRH analogue use (usually >6 months), low-dose estrogen/progesterone is "added back." * **Other Uses:** IVF (to prevent premature LH surge), Polycystic Ovary Syndrome (PCOS), and thinning the endometrium before hysteroscopic resection.

Q: Which of the following drugs cannot be used in the treatment of hirsutism in Polycystic Ovarian Disease (PCOD)?

Menopausal gonadotropin. **Explanation:** The goal of treating hirsutism in PCOD is to lower circulating androgen levels or block their action at the hair follicle. **Why Menopausal Gonadotropin is the correct answer:** Human Menopausal Gonadotropin (hMG) contains **Follicle Stimulating Hormone (FSH) and Luteal Hormone (LH)**. In PCOD, there is already a characteristic high LH:FSH ratio. Administering exogenous gonadotropins stimulates the ovaries to produce more estrogen and androgens, potentially worsening the hormonal imbalance and hirsutism. hMG is used for **ovulation induction** in infertile patients, not for treating androgenic symptoms. **Analysis of incorrect options:** * **GnRH Agonists:** Long-acting GnRH analogues cause pituitary desensitization, leading to a "medical oophorectomy." This suppresses ovarian androgen production, making it an effective (though second-line) treatment for severe hirsutism. * **Spironolactone:** This is a potassium-sparing diuretic that acts as an **androgen receptor antagonist** and inhibits 5-alpha reductase. It is a mainstay in the medical management of hirsutism. * **Metformin:** As an insulin sensitizer, it reduces hyperinsulinemia. Lower insulin levels lead to a decrease in ovarian androgen production and an increase in Sex Hormone Binding Globulin (SHBG), which reduces free testosterone. **Clinical Pearls for NEET-PG:** * **First-line treatment** for hirsutism in PCOD is usually Combined Oral Contraceptive Pills (COCPs). * **Spironolactone** must be used with contraception due to the risk of feminization of a male fetus. * **Finasteride** (5-alpha reductase inhibitor) and **Flutamide** (pure anti-androgen) are other options. * It takes **6–9 months** of therapy to see clinical improvement in hirsutism due to the long hair growth cycle.

Q: Which of the following pharmacological agents is NOT used in the management of polycystic ovarian syndrome (PCOS)?

Danazol. **Explanation:** The management of Polycystic Ovarian Syndrome (PCOS) is tailored to the patient’s primary complaint: menstrual irregularity, hyperandrogenism, or infertility. **Why Danazol is the correct answer:** Danazol is a synthetic steroid with **strong androgenic properties**. It is primarily used to suppress the pituitary-ovarian axis in conditions like endometriosis and fibrocystic breast disease. Since PCOS is already characterized by **hyperandrogenism** (elevated testosterone and androstenedione), administering Danazol would worsen clinical symptoms like hirsutism and acne. Therefore, it is contraindicated in PCOS. **Why the other options are used:** * **Oral Contraceptive Pills (OCPs):** These are the **first-line treatment** for menstrual irregularity and hirsutism in women not seeking pregnancy. They regularize cycles, protect the endometrium from hyperplasia, and increase Sex Hormone Binding Globulin (SHBG), which lowers free testosterone. * **Cyclical Progesterones:** Used in patients who cannot take OCPs. They ensure regular withdrawal bleeding, preventing endometrial hyperplasia due to "unopposed estrogen." * **Letrozole:** An aromatase inhibitor that is currently the **drug of choice (DOC) for ovulation induction** in PCOS patients struggling with infertility. **NEET-PG High-Yield Pearls:** * **DOC for Ovulation Induction in PCOS:** Letrozole (superior to Clomiphene citrate). * **DOC for Hirsutism in PCOS:** Combined OCPs (specifically those containing Cyproterone acetate or Drospirenone). * **Rotterdam Criteria:** Diagnosis requires 2 out of 3: (1) Oligo/Anovulation, (2) Clinical/Biochemical Hyperandrogenism, (3) Polycystic ovaries on USG. * **LH:FSH Ratio:** Classically elevated (3:1), though no longer a diagnostic criterion.

Q: What is the normal value of Anti-Mullerian Hormone?

2-6.8 ng/mL. **Explanation:** Anti-Mullerian Hormone (AMH) is a glycoprotein secreted by the **granulosa cells of pre-antral and small antral follicles** (less than 8mm). It serves as a reliable biochemical marker for **ovarian reserve**, reflecting the size of the primordial follicle pool. **Why Option B is Correct:** The normal physiological range for AMH in a healthy woman of reproductive age is typically **2–6.8 ng/mL**. Values in this range indicate an adequate ovarian reserve, suggesting a good potential response to controlled ovarian stimulation in ART (Assisted Reproductive Technology). **Analysis of Incorrect Options:** * **Option A ( 6.8 ng/ml):** Abnormally high levels of AMH (typically >5–7 ng/mL) are a classic diagnostic marker for **Polycystic Ovary Syndrome (PCOS)**, where there is an abundance of small antral follicles. Very high levels (>10 ng/ml) also increase the risk of Ovarian Hyperstimulation Syndrome (OHSS). **High-Yield Clinical Pearls for NEET-PG:** * **Cycle Independence:** Unlike FSH, LH, and Estradiol, AMH levels remain **stable throughout the menstrual cycle**; therefore, it can be tested on any day. * **Best Marker:** AMH is considered the best biochemical marker for ovarian reserve, while **Antral Follicle Count (AFC)** via ultrasound is the best biophysical marker. * **Clinical Use:** It is used to predict the timing of menopause and to individualize gonadotropin dosing in IVF. * **Oral Contraceptive Pills (OCPs):** AMH levels may be slightly suppressed in women taking long-term OCPs.

Question 1

A patient with spontaneous abortion presents with a history of amenorrhea and an FSH level of 6 IU/mL. What is the most likely diagnosis?

Accepted Answer

Uterine synechiae

Answer

Ovarian failure

Answer

Pregnancy

Answer

Pituitary failure

Question 2

What is the most common cause of heterosexual development in a female at the expected age of puberty?

Accepted Answer

Polycystic ovarian syndrome

Answer

Congenital Adrenal hyperplasia

Answer

Pure gonadal dysgenesis

Answer

Complete androgen insensitivity syndrome

Question 3

Hypergonadotropic hypogonadism is seen in all EXCEPT?

Accepted Answer

Down syndrome

Answer

Turner syndrome

Answer

Klinefelter syndrome

Answer

Swyer's syndrome

Question 4

Which of the following is NOT typically associated with Polycystic Ovary Syndrome?

Accepted Answer

Hypertension

Answer

Diabetes Mellitus

Answer

Obesity

Answer

Hirsutism

Question 5

A female patient presents with normal breast development but scanty pubic hair. What condition is she likely suffering from?

Accepted Answer

Testicular feminization syndrome

Answer

Turner syndrome

Answer

Mullerian agenesis

Answer

Gonadal dysgenesis

Question 6

GnRH analogues are useful in all of the following conditions except:

Accepted Answer

Hyperprolactinemia

Answer

Endometriosis

Answer

Precocious puberty

Answer

Menstrual disturbances

Question 7

Which of the following drugs cannot be used in the treatment of hirsutism in Polycystic Ovarian Disease (PCOD)?

Accepted Answer

Menopausal gonadotropin

Answer

Gonadotropin-releasing hormone (GnRH)

Answer

Spironolactone

Answer

Metformin

Question 8

A 20-year-old female presents with primary amenorrhea. She has no significant medical history and is not on any medications. Examination reveals a tall female with long extremities, normal-sized breasts with pale areolas, and sparse axillary hair. Pelvic examination shows scant pubic hair and a short, blind-ended vaginal pouch. What is the most appropriate next step in management?

Accepted Answer

Bilateral gonadectomy

Answer

No intervention is necessary

Answer

Unilateral gonadectomy

Answer

Bilateral mastectomy

Question 9

Which of the following pharmacological agents is NOT used in the management of polycystic ovarian syndrome (PCOS)?

Accepted Answer

Danazol

Answer

Oral contraceptive pills

Answer

Cyclical progesterones

Answer

Letrozole

Question 10

What is the normal value of Anti-Mullerian Hormone?

Accepted Answer

2-6.8 ng/mL

Answer

<1 ng/ml

Answer

6.8-10 ng/ml

Answer

>10 ng/ml

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?